In recent years, China's health standard system has been further improved, and the country attaches great importance to the development of pathology. Multiple policies such as the "14th Five Year Plan for Health Standardization Work" and "Quality Control Indicators for Pathology Professional Medical Care" have been introduced to promote the construction of pathology departments. Pathological diagnosis is the "gold standard" for disease diagnosis, playing an irreplaceable role in clinical diagnosis, disease prevention and control, medical research, and other aspects. With the advent of the precision medicine era, the accuracy and efficiency of pathological diagnosis directly affect the treatment plan and prognosis of patients. The construction of pathology departments has become a core link in improving the level of medical services.
According to statistics, there has been a long-standing problem of uneven distribution of medical resources and a huge shortage of pathologists in China. However, in Xizang, this phenomenon is particularly significant due to geographical location, natural environment, economic development and other factors. The shortage of professional pathologists has led to a prolonged pathological diagnosis cycle for local patients and difficulty in ensuring diagnostic accuracy, becoming a major bottleneck in improving medical services in Tibetan areas.
Located in Tongxia Village, Karuo District, Changdu City, Xizang, Changdu Maternal and Child Health Care Hospital is the only maternal and child health care institution in Changdu City that focuses on women and children and integrates medical treatment, health care, prevention, education and training. It undertakes the management and technical guidance of maternal and child public health business in ten counties and one district of Changdu City. Improving the ability of pathological diagnosis is crucial for ensuring the health of the people on this vast land.
Faced with the challenges of heavy medical tasks and scarce pathological diagnostic resources, Changdu Maternal and Child Health Hospital actively explores new paths, demonstrates forward-looking vision, actively embraces artificial intelligence technology, and injects new impetus into the development of pathology.
The AICyte@ digital pathology scanner from Ruihao Technology has been highly recognized by the hospital for its excellent performance. Their related research results have been published in two top tier journals:
《Morden Pathology》
In this study, two senior pathologists independently reviewed 32000 cervical thin-layer liquid based cytology slides, with a focus on analyzing:
1. Comparison of TBS reporting rates;
2. The correlation between cytological results and histological follow-up results;
3. Independent evaluation of AICyte@ screening efficacy.
This study indicates that:The overall average reading time of pathologists using AICyte@ auxiliary system is 22.23 seconds per slide, and the average reading speed can reach 12.90 seconds per slide when the last 6000 slides are taken (traditional manual reading takes about 180 seconds per slide). As familiarity with the system increases, the reading speed will gradually improve, greatly saving reading time compared to traditional microscope reading.
2. Compared with the original diagnosis, the diagnostic results of pathologists using AICyte@ auxiliary system showed the same sensitivity (97.89% vs 97.89%) in detecting CIN2+lesions, and the specificity was significantly improved (16.19% vs 6.77%)
《Cancer Cytopathology》
This study conducted a meta-analysis of 160000 sample data from four tertiary hospitals in China (67472 from Zhengzhou University Third Affiliated Hospital, 46060 from Peking University Shenzhen Hospital, 25667 from Shijiazhuang Obstetrics and Gynecology Hospital, and 24649 from Jinan Maternal and Child Health Hospital) to investigate the competence of AICyte@ in independently conducting cervical cancer screening with a 50% negative rejection rate.
This study indicates that:
1. The figure shows the ROC curve: for a 50% rejection rate, i.e. at a false positive rate (FPR) of 0.50, draw a vertical line intersecting each ROC curve, and the y value at the intersection point corresponds to the corresponding sensitivity or specificity.
The results of a large-scale clinical study showed that the sensitivity of HSIL, LSIL, ASC-H, AGC, and ASC-US slides were 100%, 99.69%, 98.52%, 92.93%, and 85.39%, respectively.
In a sample study with a total of 160000 cases in four hospitals, when AICyte@ was set to a negative rejection rate of 50%, there were no missed diagnoses of high-grade squamous intraepithelial lesions (HSIL).
By comparing and analyzing with historical diagnostic results, i.e. standard TBS report content, the negative conformity rate of AICyte@ interpretation results alone was 98.8%.
According to the "Cervical Cell Inspection Workflow" recommended in the study, when setting the AICyte@ negative rate to 50%, slides judged as negative by the system algorithm will no longer require manual review, greatly reducing the workload of pathologists.
These data fully demonstrate the strong strength of AICyte@ in improving diagnostic accuracy and efficiency, and have become an important basis for Changdu Maternal and Child Health Hospital to choose Ruihao products.
The high altitude, low oxygen and unstable voltage environment in Changdu, Xizang, poses a serious challenge to personnel and equipment. After sales engineers overcome numerous difficulties and strive to carry out installation and commissioning work under limited conditions. In the end, AICyte@ digital pathology scanner was successfully delivered and comprehensive operational training was provided to hospital pathology teachers to ensure that the equipment could be quickly put into use and achieve maximum efficiency.
This time, AICyte@ digital pathological scanner was successfully settled in the Changdu Maternal and Child Health Hospital in Xizang, which not only injected new energy into the precision medical treatment on the snow covered plateau, but also provided patients with efficient and accurate pathological diagnosis services, and also marked a new milestone for Ruihao Technology in assisting the development of grass-roots medical care.
In the future, Ruihao Technology will continue to innovate, continuously optimize its products and services, work with more medical institutions to jointly promote the pathological diagnosis industry to climb new heights, safeguard people's lives and health, and write a new chapter of high-quality medical development!